Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ICUI Stock Forecast 2026-2027
$142.20
Current Price
$3.55B
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ICUI Price Targets
+40.6%
To High Target of $200.00
+16.0%
To Median Target of $165.00
+12.5%
To Low Target of $160.00
ICUI Price Momentum
+4.1%
1 Week Change
+15.6%
1 Month Change
+7.7%
1 Year Change
-0.3%
Year-to-Date Change
-11.3%
From 52W High of $160.29
+32.9%
From 52W Low of $107.00
📊 TOP ANALYST CALLS
Did ICUI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ICU Medical is one of their latest high-conviction picks.
Latest ICUI Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ICUI has a bullish consensus with a median price target of $165.00 (ranging from $160.00 to $200.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $142.20, the median forecast implies a 16.0% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ICUI Analyst Ratings
7
Buy
0
Hold
0
Sell
ICUI Price Target Range
Low
$160.00
Average
$165.00
High
$200.00
Current: $142.20
Latest ICUI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ICUI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 27, 2026 | Needham | Mike Matson | Buy | Upgrade | $165.00 |
| Apr 27, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Apr 17, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Feb 20, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Feb 20, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Nov 7, 2025 | Keybanc | Overweight | Maintains | $N/A | |
| Nov 7, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| Oct 21, 2025 | Keybanc | Overweight | Maintains | $N/A | |
| Sep 10, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| Aug 15, 2025 | Piper Sandler | Overweight | Initiates | $N/A | |
| Aug 8, 2025 | Raymond James | Strong Buy | Maintains | $N/A | |
| May 9, 2025 | Raymond James | Strong Buy | Maintains | $N/A | |
| Apr 21, 2025 | Keybanc | Overweight | Maintains | $N/A | |
| Apr 8, 2025 | Needham | Hold | Reiterates | $N/A | |
| Dec 11, 2024 | Jefferies | Buy | Upgrade | $N/A | |
| Nov 13, 2024 | Keybanc | Overweight | Maintains | $N/A | |
| Nov 13, 2024 | Needham | Hold | Reiterates | $N/A | |
| Oct 15, 2024 | Keybanc | Overweight | Maintains | $N/A | |
| Oct 14, 2024 | Jefferies | Hold | Initiates | $N/A | |
| Oct 10, 2024 | Needham | Hold | Reiterates | $N/A |
Icu Medical Inc. (ICUI) Competitors
The following stocks are similar to ICU Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Icu Medical Inc. (ICUI) Financial Data
Icu Medical Inc. has a market capitalization of $3.55B with a P/E ratio of 76.5x. The company generates $2.16B in trailing twelve-month revenue with a 2.1% profit margin.
Revenue growth is -12.3% quarter-over-quarter, while maintaining an operating margin of +5.7% and return on equity of +2.3%.
Valuation Metrics
Market Cap
$3.55B
Enterprise Value
$4.61B
P/E Ratio
76.5x
PEG Ratio
-0.3x
Price/Sales
1.6x
Growth & Margins
Revenue Growth (YoY)
-12.3%
Gross Margin
+38.9%
Operating Margin
+5.7%
Net Margin
+2.1%
EPS Growth
-12.3%
Financial Health
Cash/Price Ratio
+8.2%
Current Ratio
2.3x
Debt/Equity
63.6x
ROE
+2.3%
ROA
+1.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Icu Medical Inc. (ICUI) Business Model
About Icu Medical Inc.
What They Do
Develops innovative medical devices for healthcare.
Business Model
The company operates through three main segments: Consumables, Infusion Systems, and Vital Care. It generates revenue by selling a wide range of medical devices, including infusion sets and IV pumps, to healthcare facilities globally through direct sales, independent distributors, and partnerships.
Additional Information
Founded in 1984 and based in San Clemente, California, ICU Medical Inc. is committed to enhancing patient safety and preventing infections. Its products are vital in various healthcare settings, including acute care hospitals and home care, with a strong international presence across multiple regions.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
15,000
CEO
Mr. Vivek Jain
Country
United States
IPO Year
1992
Website
www.icumed.comIcu Medical Inc. (ICUI) Latest News & Analysis
Latest News
Quick Summary
2,447 shares of Sanzone were sold for approximately $304,000, representing 11.17% of their direct holdings.
Why It Matters
Sanzone's sale of 11.17% of shares suggests potential concerns about future performance or liquidity, which could impact investor sentiment and stock price.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
ICU Medical, Inc. (ICUI) held its Q1 2026 earnings call, discussing financial performance and future outlook. Further details on revenue and market strategies were provided.
Why It Matters
ICU Medical's Q1 2026 earnings reveal financial performance, growth prospects, and operational efficiency, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
ICU Medical Announces First Quarter 2026 Results
1 month ago
Quick Summary
ICU Medical, Inc. (Nasdaq: ICUI) announced its financial results for Q1 2026, ending March 31. Further details on performance were not included in the excerpt.
Why It Matters
ICU Medical's quarterly financial results can impact stock performance, investor confidence, and market perception of its growth potential in the medical products sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ICU Medical (ICUI) reported Q3 earnings of $1.97 per share, exceeding the Zacks estimate of $1.78 and up from $1.72 per share year-over-year.
Why It Matters
ICU Medical's earnings beat estimates, indicating strong performance and growth. This can boost investor confidence and positively impact the stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors should monitor ICUI stock due to recent significant activity in the options market.
Why It Matters
Unusual options activity in ICUI stock may signal potential volatility or significant price movements, indicating a shift in investor sentiment that could impact stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
ICU Medical launched a high-volume pump with enhanced features, likely boosting retention and revenue. SiteOne Landscape Supply holds 18% of a $26B market, growing revenue steadily. Madison Small Cap Fund exited Globus Medical, now valued at $12B.
Why It Matters
ICU Medical's new pump may boost revenue and retention. SiteOne's significant market share and growth indicate stability. Globus Medical's market cap growth led to liquidation, signaling potential volatility.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About ICUI Stock
What is Icu Medical Inc.'s (ICUI) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Icu Medical Inc. (ICUI) has a median price target of $165.00. The highest price target is $200.00 and the lowest is $160.00.
Is ICUI stock a good investment in 2026?
According to current analyst ratings, ICUI has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $142.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ICUI stock?
Wall Street analysts predict ICUI stock could reach $165.00 in the next 12 months. This represents a 16.0% increase from the current price of $142.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Icu Medical Inc.'s business model?
The company operates through three main segments: Consumables, Infusion Systems, and Vital Care. It generates revenue by selling a wide range of medical devices, including infusion sets and IV pumps, to healthcare facilities globally through direct sales, independent distributors, and partnerships.
What is the highest forecasted price for ICUI Icu Medical Inc.?
The highest price target for ICUI is $200.00 from at , which represents a 40.6% increase from the current price of $142.20.
What is the lowest forecasted price for ICUI Icu Medical Inc.?
The lowest price target for ICUI is $160.00 from at , which represents a 12.5% increase from the current price of $142.20.
What is the overall ICUI consensus from analysts for Icu Medical Inc.?
The overall analyst consensus for ICUI is bullish. Out of 3 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $165.00.
How accurate are ICUI stock price projections?
Stock price projections, including those for Icu Medical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 13, 2026 8:45 PM UTC